Under the C-diff section on Immuron’s website it says- “Results for Immuron’s animal recurrence studies will be available this January. Positive results in the study would conclude that IMM-529 would be beneficial in treatments for all three phases of the disease, prevention, initial treatment, and recurrence, with recurrence being the largest unmet need
“
Anyone heard anything about the results because it is already February?
C-diff results.
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.57M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4386 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 10000 | 1 |
View Market Depth
| Last trade - 11.34am 12/09/2024 (20 minute delay) ? |
| IMC (ASX) Chart |
Day chart unavailable